[Treatment of malignant lymphoma with Peptichemio. Preliminary communication].
D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D004341:Drug Evaluation; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010689:Phlebitis / Q000139:chemically induced; D012075:Remission, Spontaneous; D013997:Time Factors
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D010455:Peptides
Wstepna ocena leczenia chłoniaków złośliwych preparatem peptichemio